Altuviiio approval allows patients to 'reimagine living with hemophilia', Sanofi boss says

The US Food and Drug Administration (FDA) has approved Altuviiio (efanesoctocog alfa), a high-sustained factor VIII replacement therapy.

Altuviiio is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management, for adults and children with hemophilia A.

"An important clinical advancement for the hemophilia community"It is the first hemophilia A treatment that delivers normal to near-normal factor activity levels for most of the week with once-weekly dosing, and significantly reduces bleeds compared to prior factor VIII prophylaxis.